Last kr93.80 SEK
Change Today -0.70 / -0.74%
Volume 263.3K
As of 8:01 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

swedish orphan biovitrum ab (SOBI) Snapshot

Open
kr94.55
Previous Close
kr94.50
Day High
kr95.00
Day Low
kr93.75
52 Week High
02/20/15 - kr95.85
52 Week Low
03/26/14 - kr65.00
Market Cap
25.8B
Average Volume 10 Days
801.0K
EPS TTM
kr-0.99
Shares Outstanding
270.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SWEDISH ORPHAN BIOVITRUM AB (SOBI)

Related News

No related news articles were found.

swedish orphan biovitrum ab (SOBI) Related Businessweek News

No Related Businessweek News Found

swedish orphan biovitrum ab (SOBI) Details

Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, is engaged in the development, manufacture, and sale of pharmaceuticals primarily in the therapeutic areas of inflammation, and genetics and metabolism diseases primarily in Europe and North America. Its principal products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases. The company also offers various products, including Defibrotide, Erwinase, Ferriprox, and Willfact for used in the haematology therapeutic area; Aloxi, Cometriq, Kepivance, Megace, Multiferon, Removab, and Yondelis for use in the oncology therapeutic area; Cyanokit, Fomepizole, Ruconest, and ViperaTAb for use as emergency medicines and antidotes; and Betapred, Buronil, Mezavant, and Xiapex for the treatment of infectious diseases and specialty care. In addition, it develops rFVIIIFc, which is under Phase III clinical trials for the treatment of hemophilia A; rFIXFc that is under Phase III clinical trials to treat hemophilia B; Kiobrina, which is under Phase III clinical trials to enhance growth in premature infants; and SOBI002, a complement C5 inhibitor, which is in Phase I clinical trials to treat genetic and metabolic diseases. The company has an agreement with Pfizer for the manufacture of drug substance for ReFacto AF/XYNTHA for the treatment of hemophilia A; and Biogen Idec for the development and commercialization of recombinant factor VIII and factor IX hemophilia programs. It also has a collaboration agreement with Auxilium Pharmaceuticals for the development, supply, and commercialization of Xiapex, a biologic for the treatment of Dupuytren’s contracture. Swedish Orphan Biovitrum AB (publ) is headquartered in Stockholm, Sweden.

584 Employees
Last Reported Date: 02/19/15

swedish orphan biovitrum ab (SOBI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr4.3M
Compensation as of Fiscal Year 2013.

swedish orphan biovitrum ab (SOBI) Key Developments

Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Alprolix(R) Paediatric Study

Biogen Idec and Swedish Orphan Biovitrum AB (publ) announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix(R) [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under age 12 with severe haemophilia B. Alprolix was generally well tolerated and no inhibitors (neutralising antibodies that may interfere with the activity of the therapy) were detected during the study. In this study, once-weekly prophylactic dosing with Alprolix resulted in low bleeding rates. Alprolix is the only approved hemophilia B therapy with prolonged circulation in the body. The successful completion of Kids B-LONG supports applications for paediatric indications in several geographies and is an important step in seeking marketing authorisation for Alprolix in Europe. The European Medicines Agency requires the inclusion of paediatric study data in the initial marketing application for a new haemophilia therapy. Interim results of the Kids B-LONG study helped support the U.S. approval of Alprolix for use in children. Kids B-LONG investigated the safety, efficacy, and pharmacokinetics (measurement of the presence of the drug in a person's body over time) of Alprolix in previously treated children under age 12 with severe haemophilia B. The study's primary endpoint was to evaluate the occurrence of inhibitor development. Secondary endpoints included the overall and spontaneous annualised bleeding rates (ABR), which is the estimated number of yearly bleeding episodes, and the number of injections used to treat bleeding episodes. In the study, children treated prophylactically with Alprolix had an overall median ABR of 1.97. The median ABR for spontaneous joint bleeds was zero. Approximately 33% of participants in the study experienced zero bleeding episodes. Overall, 91.7% of bleeding episodes were controlled by one or two injections of Alprolix. The terminal half-life of Alprolix in the study was 66.5 hours for children under six and 70.3 hours for children six to less than 12 years of age. Additional analyses of the Kids B-LONG study are ongoing, and detailed results will be presented at a future scientific meeting. No inhibitors to Alprolix were detected during the study. Alprolix was generally well tolerated and no cases of serious allergic reactions or vascular thrombotic events were reported in any participants, all of whom had been previously treated with other commercially available factor IX products. No serious adverse events were determined by any investigator to be related to the drug. One adverse event, decreased appetite, was considered related to Alprolix treatment and was reported in one participant. No participant discontinued the study due to an adverse event after receiving Alprolix. The pattern of treatment-emergent adverse events reported was consistent with the population studied and generally consistent with results seen in adolescents and adults in the pivotal Phase 3 B-LONG study.

Swedish Orphan Biovitrum AB Reports Consolidated and Parent Earnings Results for the Fourth Quarter and Full Year 2014

Swedish Orphan Biovitrum AB reported consolidated and parent earnings results for the fourth quarter and full year 2014. For the quarter, on consolidated basis, the company reported total revenues of SEK 705.3 million compared to SEK 610.8 million a year ago. Product revenues were SEK 575.3 million compared to SEK 448.0 million a year ago. EBITA was SEK 38.2 million compared to SEK 65.2 million a year ago. EBITA excluding write-downs (Multiferon) was SEK 63.4 million compared to SEK 65.2 million a year ago. LBIT was SEK 32.7 million compared to SEK 4.9 million a year ago. Profit for the period was SEK 17.4 million compared to SEK 13.4 million a year ago. Loss per share before and after dilution was SEK 0.07 compared to SEK 0.05 per share a year ago. Cash flow from operations was SEK 52.6 million compared to SEK 4.1 million a year ago. Investment in intangible fixed assets was SEK 138.1 million compared to SEK 6.5 million a year ago. Investment in tangible fixed assets was SEK 8.5 million compared to SEK 9.2 million a year ago. For the year, on consolidated basis, the company reported total revenues of SEK 2,607.0 million compared to SEK 2,176.7 million a year ago. Product revenues were SEK 1,988.8 million compared to SEK 1,557.7 million a year ago. LBITA was SEK 43.4 million compared to EBITA of SEK 211 million a year ago. EBITA excluding write-downs (Multiferon) was SEK 306.7 million compared to SEK 211.0 million a year ago. LBIT was SEK 325 million compared to SEK 66.6 million a year ago. Profit for the period was SEK 267.8 million compared to SEK 93 million a year ago. Loss per share before and after dilution was SEK 1.01 compared to SEK 0.35 per share a year ago. Cash flow from operations was SEK 233.7 million compared to SEK 185.4 million a year ago. Investment in intangible fixed assets was SEK 160.3 million compared to SEK 384.2 million a year ago. Investment in tangible fixed assets was SEK 22.9 million compared to SEK 26 million a year ago. Net debt was SEK 298.4 million compared to SEK 352.5 million a year ago. For the quarter, on parent basis, the company reported total revenues of SEK 591.6 million compared to SEK 483.6 million a year ago. Operating loss was SEK 17.9 million compared to SEK 28.3 million a year ago. Loss for the period was SEK 159.8 million compared to SEK 27.5 million a year ago. For the year, on parent basis, the company reported total revenues of SEK 2,328.3 million compared to SEK 1,841.9 million a year ago. Operating profit was SEK 196.8 million compared to operating loss of SEK 17.9 million a year ago. Loss for the period was SEK 120.7 million compared to SEK 7.6 million a year ago.

Swedish Orphan Biovitrum AB, Q4 2014 Earnings Call, Feb 19, 2015

Swedish Orphan Biovitrum AB, Q4 2014 Earnings Call, Feb 19, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SOBI:SS kr93.80 SEK -0.70

SOBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.81 EUR +0.06
Oxford Biomedica PLC 9.80 GBp +0.53
Veloxis Pharmaceuticals A/S kr0.93 DKK +0.02
View Industry Companies
 

Industry Analysis

SOBI

Industry Average

Valuation SOBI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.8x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SWEDISH ORPHAN BIOVITRUM AB, please visit www.biovitrum.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.